To Top

Community

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Contribution
Clinical Study

Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine

PR-M05-18-NI-092
FDA Review

FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

PR-M05-18-NI-090
Research Collaboration

Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

PR-M05-18-NI-093
Strategic Partnership

Evotec and Celgene Enter into Strategic Oncology Partnership

PR-M05-18-NI-091
Trial Results

RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts

PR-M05-18-NI-089
Strategic Collaboration

WuXi Biologics and Bioasis Announce Initial Strategic Collaboration

PR-M05-18-NI-087
Award

Paragon Bioservices Recognized as Life Science Company of the Year by Maryland Tech Council

PR-M05-18-NI-085
Drug Development

HistoIndex and CymaBay Therapeutics Team up to Advance NASH Drug Development

PR-M05-18-NI-084
Monoclonal Antibody

Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody

PR-M05-18-NI-083
Clinical Trial

Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3

PR-M05-18-NI-080
Collaboration

GeneNews Announces Collaboration with AIM Laboratories to Expand Test Utilization

PR-M05-18-NI-078
Phase 3 Trial

LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

PR-M05-18-NI-077
Clinical Data

Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO

PR-M05-18-NI-075
FDA Approval

FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults

PR-M05-18-NI-079
Cell and Gene Therapy

Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease

PR-M05-18-NI-074
Biologics

WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

PR-M05-18-NI-070
FDA Approval

U.S. Food and Drug Administration Approves Expanded Indication for Truvada®

PR-M05-18-NI-073
Positive Trial

Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis

PR-M05-18-NI-072
FDA Approval

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

PR-M05-18-NI-071
Clinical Data

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

PR-M05-18-NI-068
Clinical Trial

Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations

PR-M05-18-NI-065
Collaboration

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

PR-M05-18-NI-066
Acquisition

Lilly to Acquire AurKa Pharma

PR-M05-18-NI-065
Zika Test

FDA approves additional claim for Roche cobas Zika test

PR-M05-18-NI-061
Drug Development

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

PR-M05-18-NI-060
FDA Approval

Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents

PR-M05-18-NI-058
FDA Clearance

Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System

PR-M05-18-NI-059
Capacity Expansion

Marken Announces Expansion Of Cryogenic Services

PR-M05-18-NI-069
FDA Clearance

Faxitron VisionCT System Granted 510(k) Clearance for True 3D Imaging of Breast Specimens

PR-M05-18-NI-057
Preclinical Data

Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

PR-M05-18-NI-056
Oncology

Cancer Treatment Developed at Ben-Gurion University Shows Ability to Reprogram Cancer Cells to Pre-Cancerous State

PR-M05-18-NI-054
Supply Agreement

AGC Biologics Enters into Commercial Supply Agreement with MacroGenics

PR-M05-18-NI-053
Partnership

Philips, Emory Healthcare and Royal Perth Hospital in Australia partner to launch remote intensive care monitoring program

PR-M05-18-NI-055
Preclinical Results

NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate

PR-M05-18-NI-052
Collaboration

FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors

PR-M05-18-NI-051
Collaboration Agreement

Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research

PR-M05-18-NI-050
Acquisition

Lilly Announces Agreement To Acquire ARMO BioSciences

PR-M05-18-NI-049
Clinical Trials

Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib)

PR-M05-18-NI-048
Innovative Drugs

Innovative Drugs and Anti-Cancer Compounds Are Most Welcome in the Chinese Market, Says Asia-Pacific CRO George Clinical

PR-M05-18-NI-058
Strategic Collaboration

Evotec and Carna Biosciences Collaborate on Indigo Platform

PR-M05-18-NI-047
Manufacturing Agreement

Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

PR-M05-18-NI-046
FDA Inspection

Cytovance® Biologics Successfully Completes FDA Inspection

PR-M05-18-NI-044
Strategic Partnership

EA Health and Photon Announce Strategic Partnership

PR-M05-18-NI-043
Licensing Agreement

DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)

PR-M05-18-NI-042
Drug Discovery

XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery

PR-M05-18-NI-041
Endpoint

Phase III Study Evaluating the Efficacy and Safety of Lonsurf in Patients with Metastatic Gastric Cancer Meets Primary Endpoint

PR-M05-18-NI-040
Clinical Research

Worldwide Clinical Trials and Datavant Take Steps Toward Transforming Clinical Trial Success in Neurodegenerative Diseases

PR-M05-18-NI-039
Discovery Platform

Biomax Informatics Software Licensed by Global Pharma Company, Boehringer Ingelheim, to Build a Target Discovery Knowledge Platform

PR-M05-18-NI-038
Announcement

Alcami St. Louis Facility to be Honored by Missouri House of Representatives and City of St. Louis

PR-M05-18-NI-032
Research

Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research

PR-M05-18-NI-033
Drug Development

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

PR-M05-18-NI-034
IPO

WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock Exchange

PR-M05-18-NI-037
Announcement

Sanofi Named to DiversityInc's Top 50 Companies for Diversity®

PR-M05-18-NI-031
Extended Relationship

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

PR-M05-18-NI-030
Data Presentation

Janssen to Present Data in Treatment-Resistant Mental Ilnesses

PR-M05-18-NI-029
Investment

Novasep Invests €10M in "SeneFill," Its New Facility for Commercial Aseptic Fill & Finish Operations

PR-M05-18-NI-028
Prescribing Information

TRINTELLIX® Prescribing Information Now Includes New Data Showing Improvement in Processing Speed

PR-M05-18-NI-027
Clinical Trials

Merck Provides Update on KEYNOTE-407 Trial

PR-M05-18-NI-026
Acquisition

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

PR-M05-18-NI-021
FDA Approval

Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication

PR-M05-18-NI-022
Expansion

Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics

PR-M05-18-NI-023
Drug Discovery

Bactevo Enters Drug Discovery Agreement with Boehringer Ingelheim

PR-M05-18-NI-024
Collaboration

Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease

PR-M05-18-NI-025
Commercial Manufacturing Agreement

AGC Biologics Enters into Commercial Manufacturing Agreement with Horizon Pharma plc

PR-M05-18-NI-036
Authorization Application

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

PR-M05-18-NI-016
Partnership

Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific

PR-M05-18-NI-017
Collaboration

LabCorp Announces Collaboration with The Recovery Platform to Assist Physicians Treating Patients with Opioid Dependency

PR-M05-18-NI-018
Clinical Data

New Study Finds Probiotic Treatment Can Reduce Rehospitalization for Individuals with Mania

PR-M05-18-NI-019
Investment

WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

PR-M05-18-NI-011
Distribution Agreement

RenalSense Announces Distribution Agreement With Fresenius Medical Care

PR-M05-18-NI-012
Partnership

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

PR-M05-18-NI-014
Research

Sancilio Pharmaceuticals Company to Present New Research on Altemia™ to Treat Sickle Cell Disease at the ASPHO Conference

PR-M05-18-NI-015
Strategic Collaboration

Thermo Fisher and Leica Collaborate to Develop Integrated Cryotomography Workflow Solution

PR-M05-18-NI-009
Clinical Data

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL

PR-M05-18-NI-013
Clinical Trials

Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia

PR-M05-18-NI-007
Collaboration

InSysBio, LLC Announces Extension of Collaboration With GSK on Quantitative Systems Pharmacology Modeling in Asthma

PR-M05-18-NI-006
Expansion

Marken Announces Expanded Hybrid Services In Latin America

PR-M05-18-NI-015
Clinical Data

DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

PR-M04-18-NI-004
Drug Development

BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients

PR-M04-18-NI-003
Expanded Capacity

WuXi STA to Build a New R&D Center in Shanghai

PR-M05-18-NI-001
R&D

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Acquisition

LSNE Announces Acquisition Of PSC Biotech's Parenteral Manufacturing Facility

PR-M04-18-NI-99
Radiography

Samsung Announces Commitment to Lower Dose Exposure Within its Digital Radiography Suite

PR-M04-18-NI-98
Expanded Capacity

Grand River Aseptic Manufacturing, Inc. Expands Pharmaceutical Manufacturing Capacity with Major Equipment Purchase

PR-M04-18-NI-97
Strategic Collaboration

Asembia Expands Collaboration with Pfizer Oncology

PR-M04-18-NI-95
Drug Supply

Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin

PR-M04-18-NI-94
FDA

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA®(Meningococcal Group B Vaccine)

PR-M04-18-NI-92
FDA

FDA authorizes new use of test, first to identify the emerging pathogen Candida auris

PR-M04-18-NI-93
Awards

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

PR-M04-18-NI-91
Biologics

Thermo Fisher Scientific Announces $50 Million Investment to Enhance Biologics Capabilities

PR-M04-18-NI-90
Strategic Collaboration

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

PR-M04-18-NI-90
Expanded Capacity

Nelson Labs Significantly Expands Lab Operations and Testing Capabilities in Itasca, Illinois, to Better Serve Customer Needs

PR-M04-18-NI-89
Appointment

Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization

PR-M04-18-NI-87
Acquisition

P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany

PR-M04-18-NI-82
FDA Approval

US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cance

PR-M04-18-NI-83
Drug Development

Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®

PR-M04-18-NI-84
Innovation

Pear Therapeutics and Sandoz Announce Deal to Commercialize Prescription Digital Therapeutics

PR-M04-18-NI-81
Expanded Capacity

Avara Pharmaceutical Services Hold Groundbreaking at New Aiken Site

PR-M04-18-NI-86
FDA Approval

FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia

PR-M04-18-NI-80
Vaccine

Vaccibody moving forward with Cancer Neoantigen Vaccine Trial

PR-M04-18-NI-79
Clinical Development

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

PR-M04-18-NI-78
Acquisition

JLL and Water Street Announce Acquisition to Expand Global Life Sciences Commercialization Services Platform

PR-M04-18-NI-77
Acquisition

Bruker Acquires nanoIR Company Anasys Instruments

PR-M04-18-NI-76
FDA Approval

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

PR-M04-18-NI-74
Awards

WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

PR-M04-18-NI-73
Cardiovascular

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

PR-M04-18-NI-72
Artificial Intelligence

AI-Guided Cancer Therapy Platform from SRI International Identifies Novel Molecular Targets for Aggressive Form of Breast Cancer

PR-M04-18-NI-71
Donation

Grifols Donates Over 25 million International Units of Blood Clotting Factor in 2017

PR-M04-18-NI-70
Expanded Capacity

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services

PR-M04-18-NI-75
Collaboration

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford

PR-M04-18-NI-64
Oncology

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent

PR-M04-18-NI-63